Develops drug candidates for kidney disease, including a phosphate binder for dialysis patients and a treatment for acute kidney injury.
10-K for FY2025, filed Mar 30, 2026
Pharmaceutical partners license OLC rights for Greater China and select Asian markets, then handle regulatory approval and commercialization or distribution in those territories.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 16, 2026
−$7MView ↗
Loading...